✦ LIBER ✦

Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: A Gynecologic Oncology Group study

✍ Scribed by L.M. Hess; R. Barakat; C. Tian; R.F. Ozols; D.S. Alberts

Book ID: 113961169
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 208 KB
Volume: 107
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2007.06.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic factors for stage III epithel

Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study

✍ L. Landrum; J. Java; C. Mathews; G. Lanneau; L. Copeland; D. Armstrong; J. Walke 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 78 KB

Prognostic factors for high-risk early-s

Prognostic factors for high-risk early-stage epithelial ovarian cancer : A Gynecologic Oncology Group study

✍ John K. Chan; Chunqiao Tian; Bradley J. Monk; Thomas Herzog; Daniel S. Kapp; Jef 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB

## Abstract ## BACKGROUND. The purpose was to identify the factors predictive of recurrence and survival in patients with high‐risk (stage I, grade 3; stage IC, stage II, or clear cell) epithelial ovarian cancer after adjuvant therapy. ## METHODS. Data was extracted from patients who underwent p

Analysis of patient age as an independen

Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin–cyclophosphamide versus carboplatin–cyclophosphamide in stages III (suboptimal) and IV ovarian cancer: A southwest oncology group study

✍ David S. Alberts; Steve Dahlberg; Stephanie J. Green; Dava Garcia; Edward V. Han 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 888 KB

Randomized phase III trial of tamoxifen

Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study

✍ Jean A. Hurteau; Mark F. Brady; Kathleen M. Darcy; William P. McGuire; Pamela Ed 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 490 KB